Geode Capital Management LLC Has $61.65 Million Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Geode Capital Management LLC grew its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 9.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,945,455 shares of the company’s stock after purchasing an additional 172,838 shares during the period. Geode Capital Management LLC’s holdings in IDEAYA Biosciences were worth $61,645,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. FMR LLC lifted its holdings in IDEAYA Biosciences by 12.1% during the 3rd quarter. FMR LLC now owns 12,635,653 shares of the company’s stock valued at $400,297,000 after purchasing an additional 1,365,570 shares during the last quarter. RA Capital Management L.P. bought a new position in shares of IDEAYA Biosciences in the third quarter valued at approximately $42,681,000. Janus Henderson Group PLC raised its stake in shares of IDEAYA Biosciences by 26.7% in the third quarter. Janus Henderson Group PLC now owns 5,162,376 shares of the company’s stock valued at $163,518,000 after acquiring an additional 1,086,356 shares during the last quarter. Jennison Associates LLC boosted its holdings in shares of IDEAYA Biosciences by 136.6% in the 3rd quarter. Jennison Associates LLC now owns 972,266 shares of the company’s stock worth $30,801,000 after acquiring an additional 561,404 shares in the last quarter. Finally, State Street Corp grew its position in IDEAYA Biosciences by 15.4% during the 3rd quarter. State Street Corp now owns 3,317,936 shares of the company’s stock worth $105,112,000 after acquiring an additional 443,640 shares during the last quarter. Institutional investors and hedge funds own 98.29% of the company’s stock.

IDEAYA Biosciences Trading Up 3.3 %

NASDAQ:IDYA opened at $25.61 on Friday. The firm has a market capitalization of $2.21 billion, a price-to-earnings ratio of -10.99 and a beta of 0.79. IDEAYA Biosciences, Inc. has a 1-year low of $24.48 and a 1-year high of $47.74. The business’s 50-day moving average price is $28.28 and its two-hundred day moving average price is $33.98.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings data on Monday, November 4th. The company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.03. During the same quarter in the prior year, the business posted ($0.46) EPS. Sell-side analysts predict that IDEAYA Biosciences, Inc. will post -2.45 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on IDYA. Leerink Partnrs downgraded IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 5th. Royal Bank of Canada reiterated an “outperform” rating and set a $61.00 price target on shares of IDEAYA Biosciences in a research report on Tuesday, September 24th. Stephens started coverage on shares of IDEAYA Biosciences in a research report on Monday, November 18th. They issued an “overweight” rating and a $51.00 price objective for the company. Leerink Partners lowered shares of IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $41.00 to $27.00 in a research report on Tuesday, November 5th. Finally, Oppenheimer reissued an “outperform” rating and issued a $53.00 price target on shares of IDEAYA Biosciences in a report on Tuesday, October 29th. Two analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $53.67.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.